Michael LeekChief Executive Officer at TC BioPharm
Recently presented the 'Scottish Life-Sciences Entrepreneurial Business Leadership' award; Michael is CEO of TC BioPharm, developing clinical phase CAR-T cancer immunotherapies.
He has previously worked as CEO of an orthobiologicals company, and with a clinical team developing an autologous infusion of stem cells to initiate regeneration of new hepatic tissue. Michael was jointly responsible for moving Intercytex from a pre-clinical research company, to an AIM-listed biotech with several cell therapy products in the clinic. Michael is also a Fellow of the Royal Society of Medicine and Honorary Lecturer at the University of Aberdeen, School of Medical Sciences